Abcellera Biologics IncNASDAQ:ABCL
- LAST PRICE2.9000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.9000/ 6
- Ask / Lots2.9300/ 1
- Open / Previous Close0.0000 / 2.9000
- Day Range---
- 52 Week Range
- Volume9,795
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ABCL |
|---|---|---|
| 09:32 ET | 22180 | 2.9562 |
May 28, 2024
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, from 4:05PM ET on Tuesday May 28, 2024 by Dow Jones
4:05PM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Abcellera Biologics Inc | 852.8M | -5.7x | --- |
Relay Therapeutics Inc | 921.2M | -2.6x | --- |
CureVac NV | 731.2M | -2.5x | --- |
Tango Therapeutics Inc | 1.1B | -9.1x | --- |
Bicycle Therapeutics PLC | 1.0B | -4.7x | --- |
Mereo BioPharma Group PLC | 608.1M | -12.7x | --- |
Company Information
AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.
Contact Information
- Headquarters
- 2215 Yukon StreetVANCOUVER, BC, Canada V5Y 0A1
- Phone
- 604-559-9005
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Carl Hansen
- Co-Founder, Chief Operating Officer, Director
- Veronique Lecault
- Chief Financial Officer
- Andrew Booth
- Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
- Tryn Stimart
- Independent Director
- Michael Hayden
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $852.8M |
|---|---|
Revenue (TTM) | $35.8M |
Shares Outstanding | 294.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.38 |
EPS | $-0.51 |
Book Value | $3.96 |
P/E Ratio | -5.7x |
Price/Sales (TTM) | 23.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -634.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
